| Opicapone for adjunctive treatment of motor signs and symptoms in Parkinson's disease TS ID 11941 | Technology appraisal guidance |
| Oral semaglutide for managing overweight and obesity [ID6188] | Technology appraisal guidance |
| Orforglipron for managing overweight and obesity [ID6516] | Technology appraisal guidance |
| Osimertinib for neoadjuvant treatment of EGFR mutation-positive resectable non-small-cell lung cancer [ID6472] | Technology appraisal guidance |
| Osteoporosis | Quality standard |
| OTL-101 for treating adenosine deaminase deficiency–severe combined immunodeficiency [ID1152] | Highly specialised technology |
| Ovarian, fallopian tube, peritoneal cancer (platinum sensitive) - rucaparib (with nivolumab, maintenance, after 1 therapy) [ID6128] | Technology appraisal guidance |
| Pain management (young people and adults) | Quality standard |
| Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846] | Technology appraisal guidance |
| Pancreatitis (including acute pancreatitis) | Quality standard |
| Pariglasgene brecaparvovec for treating glycogen storage disease type 1a in people 8 years and over [TSID11865] | Technology appraisal guidance |
| Patritumab deruxtecan for treating EGFR mutation-positive advanced non-small-cell lung cancer after 1 or 2 tyrosine kinase inhibitor treatment [ID6467] | Technology appraisal guidance |
| Pegargiminase with pemetrexed and cisplatin for untreated advanced malignant pleural
mesothelioma [ID1575] | Technology appraisal guidance |
| Pegcetacoplan for treating primary complement 3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over [ID6489] | Technology appraisal guidance |
| Pelacarsen for reducing the risk of cardiovascular events in people with established cardiovascular disease and hyperlipidaemia [ID6559] | Technology appraisal guidance |
| Pelvic floor dysfunction | Quality standard |
| Pembrolizumab adjuvant for urothelial carcinoma and/or localised muscle invasive bladder cancer [TSID12021] | Technology appraisal guidance |
| Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994] | Technology appraisal guidance |
| Pembrolizumab for neoadjuvant and with radiotherapy for adjuvant treatment of newly diagnosed resectable locally advanced squamous cell head and neck cancer [ID6477] | Technology appraisal guidance |
| Pembrolizumab with BCG for treating high-risk non-muscle-invasive bladder cancer [ID6271] | Technology appraisal guidance |
| Pembrolizumab with chemoradiation for untreated high-risk advanced cervical cancer [TSID10690] | Technology appraisal guidance |
| Pembrolizumab with chemoradiation for untreated muscle-invasive non-metastatic bladder cancer [TSID11953] | Technology appraisal guidance |
| Pembrolizumab with chemoradiation, then with or without olaparib, for untreated unresectable locally advanced non-small-cell lung cancer [ID6399] | Technology appraisal guidance |
| Pembrolizumab with chemoradiotherapy for untreated unresectable oesophageal cancer [ID6270] | Technology appraisal guidance |
| Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [TSID11808] | Technology appraisal guidance |
| Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6219] | Technology appraisal guidance |
| Pembrolizumab with chemotherapy for treating hormone receptor-positive HER2-negative locally recurrent inoperable or metastatic breast cancer [ID6285] | Technology appraisal guidance |
| Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853] | Technology appraisal guidance |
| Pembrolizumab with enzalutamide and androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer [TSID11810] | Technology appraisal guidance |
| Pembrolizumab with lenvatinib and chemotherapy for untreated metastatic squamous cell oesophageal cancer [TSID12096] | Technology appraisal guidance |
| Pembrolizumab with neoadjuvant chemotherapy and adjuvant endocrine therapy for treating ER-positive, HER2-negative early breast cancer [ID3993] | Technology appraisal guidance |
| Pembrolizumab with olaparib and chemoradiation for
previously untreated limited-stage small-cell lung cancer [ID6412] | Technology appraisal guidance |
| Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy [ID1587] | Technology appraisal guidance |
| Percutaneous insertion of a cerebral protection device to prevent cerebral embolism during TAVI | Interventional procedures guidance |
| Percutaneous insertion of a temporary heart pump for left ventricular haemodynamic support in high-risk percutaneous coronary interventions | Interventional procedures guidance |
| Percutaneous insertion of a temporary heart pump for left ventricular haemodynamic support in high-risk percutaneous coronary interventions | Interventional procedures guidance |
| Perioperative care | Quality standard |
| Pernicious anaemia | Quality standard |
| Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma untreated with a BTK inhibitor [ID6493] | Technology appraisal guidance |
| Pirtobrutinib with venetoclax and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma [TSID12182] | Technology appraisal guidance |
| Plinabulin with docetaxel for previously treated advanced non-small-cell lung cancer [ID3895] | Technology appraisal guidance |
| PLX-PAD for treating muscle injury after arthroplasty for hip fracture in people 60 to 90 years [ID3989] | Technology appraisal guidance |
| Povorcitinib for treating moderate to severe active hidradenitis suppurativa after a TNF-alpha inhibitor [TSID12186] | Technology appraisal guidance |
| Prevention of dementia | Quality standard |
| Pridopidine for treating Huntington's disease [ID6525] | Technology appraisal guidance |
| Primary hyperparathyroidism | Quality standard |
| Prostate cancer (hormone relapsed, homologous recombination deficiency, metastatic) – rucaparib (after 1 therapy) [ID6127] | Technology appraisal guidance |
| PXT3003 for treating Charcot-Marie-Tooth disease type 1A in people aged 16 and over [TSID9130] | Technology appraisal guidance |
| Radium-223 dichloride with enzalutamide for treating asymptomatic or mildly symptomatic hormone-relapsed metastatic prostate cancer with bone metastases [ID6512] | Technology appraisal guidance |
| Ranibizumab port delivery system for treating diabetic macular oedema [ID6137] | Technology appraisal guidance |